VDPHL01 Hits Phase 2 Endpoints in Female Hair Loss, Expanding Market Potential
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics' oral hair loss drug VDPHL01 met its Phase 2 endpoints in female pattern hair loss, showing robust hair count increases of 22.7–23.3 hairs/cm² at 6 months and high patient satisfaction. The safety profile was clean with no serious cardiac events, a key differentiator. This follows the April 2026 positive Phase 2/3 data in males and the subsequent $389M capital raise that extended cash runway into 2030. The female indication significantly expands the addressable market. Topline Phase 2/3 results in females are expected in 1H 2027, which could support a registration path.
At the time of this announcement, MANE was trading at $118.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $32.00 to $131.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.